Does treatment with anti-IL-17 affect HbA1c levels?

Published: 9 March 2020| Version 2 | DOI: 10.17632/sdxz72mzn2.2
Christopher Willy Schwarz, Nikolai Dyrberg Loft, Claus Zachariae, Lone Skov


Data on 71 patients with psoriasis. We aimed to assess the potential correlation between PASI and HbA1c and investigate the antidiabetic role of anti-IL-17A and anti-IL-12/-23. Only biologic-naïve patients were included. Description of column values: PASI1: PASI at baseline PASI2: First PASI measurement available after at least 120 days of treatment. HbA1c1: HbA1c at baseline (measured maximum 90 days before beginning treatment) HbA1c2: First HbA1c measurement available after at least 120 days of treatment. We used Spearman’s rank correlation coefficient to assess the relationship between baseline PASI scores and HbA1c levels. Additionally, to compare changes in HbA1c, we used the Wilcoxon signed rank test as data were not normally distributed. We found no correlation between PASI scores and HbA1c levels and no evidence for an overall change in HbA1c related to biologic treatment with secukinumab or ustekinumab.